Dotmatics: New and Improved Enterprise Scientific Platform
Dotmatics has launched a new enterprise scientific platform that integrates popular applications like SnapGene, Geneious, and GraphPad Prism to provide end-to-end solutions for biology, chemistry, and formulation R&D, addressing data management challenges by connecting and organizing distributed scientific data to enable faster, accurate, and collaborative research for over 2 million scientists and 10,000 customers worldwide.
Introducing the New Dotmatics
Dotmatics now includes the Dotmatics enterprise scientific platform along with popular applications such as SnapGene, Geneious, and GraphPad Prism. This combination offers end-to-end solutions for research and development in biology, chemistry, and formulations.
Our vision for a new lab of the future aims to change the course of scientific research and development. The science R&D industry is undergoing a digital transformation, with rapid growth in pharmaceutical drug discovery and chemicals and materials innovation. This rapid pace brings a proliferation of data and corresponding data management challenges, making it difficult to use scientific data effectively. The industry has lacked an integrated R&D platform with the depth, breadth, and connectivity to leading science applications needed to address these complex data challenges.
Dotmatics is addressing this gap by offering solutions designed to realize the vision of the lab of the future. Our platform connects and organizes data distributed across organizations or industries and integrates it with market-leading science applications. This enables quick access, collaboration, and informed decision-making. Our applications address the challenges faced by individual scientists, while the platform addresses organizational challenges related to finding, sharing, and extracting data.
More than 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. This mission is shared with our customers.
Bringing together our acquired brands under the Dotmatics umbrella and mission is the first step in our journey to providing true end-to-end solutions. These solutions provide structure and empower researchers to move faster with accuracy and context.
For more information about our integrated solutions, see our most recent press release.
Related
From Foundational to Aspirational: Dotmatics CEO on the Three Phases of R&D Digital Transformation
Dotmatics CEO outlines the accelerating digital transformation in life sciences R&D driven by exploding data volumes, emphasizing the shift towards AI and machine learning despite unique industry challenges such as lack of standardized interoperability and a fragmented ecosystem, which complicate progress toward a predictive, generative AI-enabled future in drug discovery.
Our 11 Most-Read Blogs of 2023: AI, Biologics, ELNs, and More
Dotmatics' top blogs of 2023 highlight key scientific advancements including the convergence of small molecule and biologic drug development, the integration and comparison of LIMS and ELN systems for enhanced lab data management, and strategies to minimize human errors in biologics research through automation and calibration.
Dotmatics Streamlines Workflow for Antibody Research
Dotmatics has launched its Biology Solution for Antibody Discovery, a cloud-based, end-to-end software platform that integrates with popular scientific tools like Geneious, SnapGene, and GraphPad Prism to centralize data management, automate workflows, reduce errors, and accelerate antibody research amid a rapidly growing antibody therapy market projected to reach up to $700 billion by 2032.
Dotmatics Appoints Mike McKee as President and CEO
Dotmatics Ltd has appointed experienced technology CEO Mike McKee as its new President to accelerate the company's growth, scale its global team, double R&D investments, and lead integration efforts within Insightful Science's portfolio, succeeding founder Stephen Gallagher who will focus on strategic growth initiatives.
Dotmatics Customers
Over 2 million scientists worldwide rely on Dotmatics products, which have been praised by leading organizations like BASF, Debiopharm, Novartis, Merck, and Nanjing Medical University for enhancing research efficiency and providing superior tools such as Geneious, Prism, and SnapGene.
Dotmatics Set to Transform the Future of Scientific Software and Data Management
Dotmatics, formed from the merger of Insightful Science and Dotmatics, is launching a powerful integrated enterprise R&D platform combining its scientific software with popular applications like SnapGene, Geneious, and GraphPad Prism to address complex data challenges and accelerate scientific research and collaboration for over two million scientists and 10,000 customers worldwide.